+

WO1998010757A3 - Utilisation d'antagonistes fonctionnels du n-methyl-d-aspartate pour reduire ou prevenir l'ototoxicite induite par l'aminoglucoside - Google Patents

Utilisation d'antagonistes fonctionnels du n-methyl-d-aspartate pour reduire ou prevenir l'ototoxicite induite par l'aminoglucoside Download PDF

Info

Publication number
WO1998010757A3
WO1998010757A3 PCT/US1997/016605 US9716605W WO9810757A3 WO 1998010757 A3 WO1998010757 A3 WO 1998010757A3 US 9716605 W US9716605 W US 9716605W WO 9810757 A3 WO9810757 A3 WO 9810757A3
Authority
WO
WIPO (PCT)
Prior art keywords
aminoglycoside
ameliorate
functional
induced ototoxicity
methyl
Prior art date
Application number
PCT/US1997/016605
Other languages
English (en)
Other versions
WO1998010757A9 (fr
WO1998010757A2 (fr
Inventor
Anthony S Basile
Phil Skolnick
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Priority to AU44246/97A priority Critical patent/AU4424697A/en
Publication of WO1998010757A2 publication Critical patent/WO1998010757A2/fr
Publication of WO1998010757A3 publication Critical patent/WO1998010757A3/fr
Publication of WO1998010757A9 publication Critical patent/WO1998010757A9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des antagonistes fonctionnels du NMDA et leur capacité à réduire l'ototoxicité provoquée par l'aminoglucoside. Ces compositions sont utiles dans le traitement ou la prévention d'une perte d'audition et/ou d'une perte d'équilibre. Une composition pharmaceutique comprenant un aminoglucoside et au moins un antagoniste fonctionnel des récepteurs de NMDA administré simultanément assurent une activité bactéricide et une protection contre l'ototoxicité induite par l'aminoglucoside.
PCT/US1997/016605 1996-09-11 1997-09-11 Utilisation d'antagonistes fonctionnels du n-methyl-d-aspartate pour reduire ou prevenir l'ototoxicite induite par l'aminoglucoside WO1998010757A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU44246/97A AU4424697A (en) 1996-09-11 1997-09-11 The use of functional n-methyl-d-aspartate antagonists to ameliorate or prevent aminoglycoside-induced ototoxicity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71247796A 1996-09-11 1996-09-11
US08/712,477 1996-09-11

Publications (3)

Publication Number Publication Date
WO1998010757A2 WO1998010757A2 (fr) 1998-03-19
WO1998010757A3 true WO1998010757A3 (fr) 1998-05-14
WO1998010757A9 WO1998010757A9 (fr) 1998-07-23

Family

ID=24862272

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/016605 WO1998010757A2 (fr) 1996-09-11 1997-09-11 Utilisation d'antagonistes fonctionnels du n-methyl-d-aspartate pour reduire ou prevenir l'ototoxicite induite par l'aminoglucoside

Country Status (2)

Country Link
AU (1) AU4424697A (fr)
WO (1) WO1998010757A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1201234A3 (fr) * 2000-09-21 2003-03-12 Tinnitus Forschungs- und Entwicklungs GmbH Traitement de maladies avec des dérivés adamantanes
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
US20060063802A1 (en) 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US8268866B2 (en) 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US9072662B2 (en) 2004-03-29 2015-07-07 Auris Medical Ag Methods for the treatment of tinnitus induced by cochlear excitotoxicity
CN104840416A (zh) * 2005-09-28 2015-08-19 奥里斯医学股份有限公司 治疗内耳疾病的药用组合物
ME01956B (me) 2005-09-28 2015-05-20 Auris Medical Ag Farmaceutske kompozicije za tretman poremećaja unutrašnjeg uva
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
KR20090115951A (ko) 2007-03-01 2009-11-10 프로비오드룩 아게 글루타미닐 사이클라제 저해제의 신규 용도
EP2139461A2 (fr) * 2007-03-20 2010-01-06 Recepticon Aps Prévention de la néphrotoxicité iii
EP2142514B1 (fr) 2007-04-18 2014-12-24 Probiodrug AG Dérivés de thio-urée utilisés comme inhibiteurs de la glutaminyl cyclase
BRPI0816712A2 (pt) 2007-09-12 2016-11-08 Merz Pharma Gmbh & Co Kgaa terapia de intervalo para o tratamento de tinnitus
ES2548913T3 (es) 2009-09-11 2015-10-21 Probiodrug Ag Derivados heterocíclicos como inhibidores de glutaminil ciclasa
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
KR101790806B1 (ko) 2010-03-10 2017-11-20 프로비오드룩 아게 글루타미닐 사이클라제(ｑｃ, ｅｃ 2.3.2.5)의 헤테로사이클릭 억제제
EP2560953B1 (fr) 2010-04-21 2016-01-06 Probiodrug AG Inhibiteurs de glutaminyl cyclase
EP2686313B1 (fr) 2011-03-16 2016-02-03 Probiodrug AG Dérivés de benzimidazole en tant qu'inhibiteurs de la glutaminyl cyclase
EP2790686B1 (fr) 2011-12-12 2021-03-10 Zilentin Ag Traitement de l'acouphène par modulation du co-transporteur chlorure nkcc1 dans le système auditif
WO2013178763A1 (fr) * 2012-05-30 2013-12-05 Sensorion Procédés pour traiter une vestibulotoxicité
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001096A1 (fr) * 1993-06-29 1995-01-12 Shapiro Howard K Compositions pharmaceutiques et leur utilisation pour le traitement d'affections neurologiques et de symptomologies a etiologies associees
WO1996000073A1 (fr) * 1994-06-23 1996-01-04 Massachusetts Eye And Ear Infirmary Traitement de la nevrite optique
WO1997023214A1 (fr) * 1995-12-22 1997-07-03 Warner-Lambert Company Analogues de piperidine a substitution en position 4 et utilisation de ces derniers en tant qu'antagonistes selectivement actifs contre les sous-types du recepteurs de nmda

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001096A1 (fr) * 1993-06-29 1995-01-12 Shapiro Howard K Compositions pharmaceutiques et leur utilisation pour le traitement d'affections neurologiques et de symptomologies a etiologies associees
WO1996000073A1 (fr) * 1994-06-23 1996-01-04 Massachusetts Eye And Ear Infirmary Traitement de la nevrite optique
WO1997023214A1 (fr) * 1995-12-22 1997-07-03 Warner-Lambert Company Analogues de piperidine a substitution en position 4 et utilisation de ces derniers en tant qu'antagonistes selectivement actifs contre les sous-types du recepteurs de nmda

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BASILE ET AL: "N-Methyl-D-Aspertate Antagonists Limit Aminoglycoside Antibiotic-Induced Hearing Loss", NATURE MEDICINE, vol. 2, no. 12, - December 1996 (1996-12-01), pages 1338 - 1343, XP002053270 *
EHRENBERGER AND FELIX: "Receptor Pharmacological Models for Inner Ear Therapies with Emphasis on Glutamate Receptors: A Survey", ACTA OTOLARYNGOLIA, vol. 115, no. 2, 1995, pages 236 - 240, XP000609443 *
JANSSEN: "Glutamate Neurotoxicity in the Developing Rat Cochlea is Antagonized by Kynurenic Acid and MK801", BRAIN RESEARCH, vol. 590, no. 1/2, - 1992, pages 201 - 206, XP002053268 *
KULAGOWSKI: "Glycine-site NMDA Receptor Antagonists: An Update.", EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 6, no. 10, 1996, pages 1069 - 1079, XP002055235 *
LEVY ET AL: "Comparison of Delayed Administration of Competitive and Non-Competitive Antagonists in Preventing NMDA Receptor-Mediated Neuronal Death", NEUROLOGY, vol. 40, - 1990, pages 852 - 855, XP002053272 *
LIU AND FECHTER: "MK801 Protects Against Carbon Monoxide-Induced Hearing Loss", TOXICOLOGY AND APPLIED PHARMACOLOGY, vol. 132, no. 2, - 1995, pages 196 - 202, XP002053269 *
PELLEGRINI ET AL: "Delayed Administration of Memantine Prevents NMDA Receptor Mediated Neurotoxicity", ANNALS OF NEUROLOGY, vol. 33, no. 4, - 1993, pages 403 - 407, XP002053273 *
PUJOL ET AL: "Implication of Non-NMDA and NMDA Receptors in Cochlear Ischaemia", NEUROREPORT, vol. 3, no. 4, - 1992, pages 299 - 302, XP002053271 *
PULLAN ET AL: "Neomycin is an Agonist at a Polyamine Site on the NMDA Receptor", JOURNAL OF NEUROCHEMISTRY, vol. 59, no. 6, 1992, pages 2087 - 2093, XP002056860 *

Also Published As

Publication number Publication date
WO1998010757A2 (fr) 1998-03-19
AU4424697A (en) 1998-04-02

Similar Documents

Publication Publication Date Title
WO1998010757A3 (fr) Utilisation d'antagonistes fonctionnels du n-methyl-d-aspartate pour reduire ou prevenir l'ototoxicite induite par l'aminoglucoside
HUP9603298A3 (en) Heterocyclic compounds having tachykinin receptor antagonist activity, their preparation, and their use for the preparation of pharmaceutical compositions
HUP9900605A3 (en) Lipopolyamines as transfection agents, preparation and use thereof and pharmaceutical compositions containing them
WO2001085257A3 (fr) Compositions d'antagoniste opioide et formes de dosage
IL116323A0 (en) Tachykinin antagonists their preparation and pharmaceutical compositions containing them
IL122345A0 (en) Benzamide derivatives their use as vasopressin antagonists processes for the preparation thereof and pharmaceutical compositions containing the same
HUP9901199A3 (en) Tropane-derivatives, inhibiting neurotransmitter re-uptake, their preparation, pharmaceutical compositions containing them and use of the compounds
AU3254395A (en) Use of a combination product that contains a competitive progesterone antagonist and a gestagen for the production of a pharmaceutical agent for treating endometriosis or leiomyomata uteri
ZA962886B (en) Substituted 1-phenyl-3-pyrazolecarboxamides active on neurotensin receptors their preparation and pharmaceutical compositions containing them
EP0841936A4 (fr) Compositions d'agents therapeutiques de conjugaison stabilises, formulation d'administration et de diagnostic les contenant
HUP0102206A2 (hu) Delavirdint tartalmazó tabletta formájú készítmény
HUP0102579A3 (en) Peptide antiangiogenic drugs, pharmaceutical compositions comprising thereof and their use
IL117349A0 (en) N-(3-benyofuranyl) urea-derivatives their preparation and pharmaceutical compositions containing them
IL115324A0 (en) Neurokinin antagonist compounds their preparation and pharmaceutical compositions containing them
IL116746A0 (en) Use of 3, 4-diphenyl chromans for the preparation of pharmaceutical compositions
IL117815A0 (en) Ascomycins their preparation and pharmaceutical compositions containing them
ZA962900B (en) Taxoids their preparation and pharmaceutical compositions which contain them
HU9503624D0 (en) Use of p antagonist in pharmaceutical compositions
IL107431A0 (en) Substituted penems and derivatives therof, their preparation and pharmaceutical compositions comprising them
GR3036410T3 (en) Taxoids, their preparation and pharmaceutical compositions containing them
TR200200913T2 (tr) Bir NK1 reseptörü antagonistini ve bir gaba yapısal analoğunun sinerjik kombinasyonları.
HUP0002929A3 (en) 2-acylaminopropanamines as tachykinin receptor antagonists and pharmaceutical compositions containing the same
IL117760A0 (en) Taxoids, their preparation and pharmaceutical compositions containing them
IL116745A (en) Use of 3,4-diphenyl chromans for the preparation of pharmaceutical compositions for treating hyperlipoproteinaemia and hypercholesterolaemia
IL127518A (en) Substituted heterocyclic benzocycloalkenes, their preparation and pharmaceutical compositions having an analgesic effect

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGES 1/6, 3/6 AND 5/6, DRAWINGS, REPLACED BY NEW PAGES 1/7, 3/7, 4/7 AND 6/7; PAGES 2/6, 4/6 AND 6/6 RENUMBERED AS PAGES 2/7, 5/7 AND 7/7; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998514006

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载